Comparing RegeneRx Biopharmaceuticals (RGRX) & Alexza Pharmaceuticals (ALXA)
RegeneRx Biopharmaceuticals (OTCMKTS: RGRX) and Alexza Pharmaceuticals (OTCMKTS:ALXA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.
This table compares RegeneRx Biopharmaceuticals and Alexza Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares RegeneRx Biopharmaceuticals and Alexza Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
RegeneRx Biopharmaceuticals has higher revenue and earnings than Alexza Pharmaceuticals. RegeneRx Biopharmaceuticals is trading at a lower price-to-earnings ratio than Alexza Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
0.2% of RegeneRx Biopharmaceuticals shares are held by institutional investors. 12.1% of RegeneRx Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for RegeneRx Biopharmaceuticals and Alexza Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
RegeneRx Biopharmaceuticals currently has a consensus price target of $1.50, indicating a potential upside of 552.46%.
RegeneRx Biopharmaceuticals beats Alexza Pharmaceuticals on 5 of the 8 factors compared between the two stocks.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
Alexza Pharmaceuticals Company Profile
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company’s product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.
Receive News & Ratings for RegeneRx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.